Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neosalus is a prescription topical skin barrier emollient developed by Exeltis USA for the management of various dermatoses, including dry skin, atopic dermatitis, and allergic contact dermatitis. It is formulated as a fragrance-free, non-comedogenic, water-soluble dressing containing active components such as free fatty acids, dimethicone, and glycerin. Neosalus works by forming a protective barrier on the skin surface to lock in moisture and shield the skin from external irritants. It is available in cream, foam, and lotion formulations and is classified as a prescription medical device. Clinical evaluations have also explored its potential antimicrobial properties against pathogens like *Escherichia coli* and methicillin-resistant *Staphylococcus aureus* (MRSA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neosalus (Exeltis).